Evidence map›Paper›PMID 9584163›Full record

ArticleMolecular and cellular biology1998

Cooperation among multiple transcription factors is required for access to minimal T-cell receptor alpha-enhancer chromatin in vivo.

C Hernandez-Munain, J L Roberts, M S Krangel

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular biology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. T-cell receptor α enhancer is inactivated in αβ T lymphocytes.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Transcriptional regulatory cascades in development: initial rates, not steady state, determine network kinetics.Proceedings of the National Academy of Sciences of the United States of America · 2003
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

C Hernandez-MunainDepartment of Immunology, Duke University Medical Center, Durham, North Carolina 27710, USA.
J L Roberts
M S Krangel
Duke Medical Center · US

Funding

Control Of Tcr Delta And Tcr Alpha RearrangementR37GM041052 · NIGMS · DUKE UNIVERSITY · PI KRANGEL, MICHAEL S · 2006 to 2015
$5.1M
HUMAN GAMMA DELTA T CELL RECEPTORR01GM041052 · NIGMS · DUKE UNIVERSITY · PI KRANGEL, MICHAEL S · 1989 to 2019
$4.8M
NIGMS NIH HHS GM41052NIGMS NIH HHS R01 GM041052NIGMS NIH HHS R37 GM041052
6 · The paper itself

Abstract

To understand the molecular basis for the dramatic functional synergy between transcription factors that bind to the minimal T-cell receptor alpha enhancer (Ealpha), we analyzed enhancer occupancy in thymocytes of transgenic mice in vivo by genomic footprinting. We found that the formation of a multiprotein complex on this enhancer in vivo results from the occupancy of previously identified sites for CREB/ATF, TCF/LEF, CBF/PEBP2, and Ets factors as well as from the occupancy of two new sites 5' of the CRE site, GC-I (which binds Sp1 in vitro) and GC-II. Significantly, although all sites are occupied on a wild-type Ealpha, all sites are unoccupied on versions of Ealpha with mutations in the TCF/LEF or Ets sites. Previous in vitro experiments demonstrated hierarchical enhancer occupancy with independent binding of LEF-1 and CREB. Our data indicate that the formation of a multiprotein complex on the enhancer in vivo is highly cooperative and that no single Ealpha binding factor can access chromatin in vivo to play a unique initiating role in its assembly. Rather, the simultaneous availability of multiple enhancer binding proteins is required for chromatin disruption and stable binding site occupancy as well as the activation of transcription and V(D)J recombination.

Indexed as

Enhancer Elements, GeneticAnimalsBase SequenceChromatinDNA-Binding ProteinsDNA FootprintingGene Expression RegulationLymphoid Enhancer-Binding Factor 1Macromolecular SubstancesMiceMolecular Sequence DataMultiprotein ComplexesReceptors, Antigen, T-Cell, alpha-betaTranscription FactorsChromatinDNA-Binding ProteinsLef1 protein, mouseLymphoid Enhancer-Binding Factor 1Macromolecular SubstancesMultiprotein ComplexesReceptors, Antigen, T-Cell, alpha-betaTranscription Factors

Identifiers

PMID9584163
PMCPMC108904
OpenAlexW1939999201

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.